Endometrial ultrasound features associated with methotrexate success in tubal ectopic pregnancy: a prospective case series.
Endometrial ultrasound features may provide additional insights into the likelihood of methotrexate success in treating tubal ectopic pregnancy, but findings should be interpreted cautiously.
Where it sits
this study against the rest of the hcg (human chorionic gonadotropin) corpusSummary and findings
This study measured the association between endometrial ultrasound features and treatment success in women with tubal ectopic pregnancy receiving methotrexate. A total of 177 women were treated with a single intramuscular dose of 50 mg/m² methotrexate. Treatment success was defined as a ≥15% decline in serum β-hCG from day 4 to day 7 after treatment.
Abstract
<h4>Background</h4>Ectopic pregnancy is an important cause of maternal morbidity in early pregnancy. Single-dose methotrexate is commonly used for haemodynamically stable women with unruptured tubal ectopic pregnancy, but treatment success varies. The association between pre-treatment endometrial ultrasonographic features and treatment outcome remains uncertain.<h4>Methods</h4>This prospective case series included 177 women with confirmed tubal ectopic pregnancy who received a single intramuscular dose of methotrexate (50 mg/m<sup>2</sup>) at two tertiary hospitals in Isfahan, Iran, between January and December 2024. Transvaginal ultrasonography was used to measure endometrial thickness and classify the endometrial echo pattern as homogeneous or triple-layer. Treatment success was defined as a ≥ 15% decline in serum β-hCG from day 4 to day 7 after treatment, followed by weekly monitoring until the concentration became undetectable. Associations with treatment success were assessed using univariable logistic regression.<h4>Results</h4>Treatment success occurred in 94 of 177 women (53.1%). Responders had lower median baseline β-hCG concentrations (500 versus 1400 mIU/mL; <i>P</i> < 0.001), thinner endometrium (7 versus 9 mm; <i>P</i> = 0.009), and a higher proportion of homogeneous endometrial appearance (65.9 versus 49.4%; <i>P</i> = 0.026). In univariable logistic regression, baseline β-hCG (<i>P</i> = 0.003), ectopic pregnancy size (<i>P</i> = 0.013), and homogeneous endometrial appearance (<i>P</i> = 0.027) were significantly associated with treatment success; endometrial thickness showed borderline evidence of association (<i>P</i> = 0.0498).<h4>Conclusion</h4>Baseline β-hCG, ectopic pregnancy size, and endometrial appearance were associated with single-dose methotrexate success in univariable analyses, while endometrial thickness showed a borderline association. Because no multivariable model was fitted, these findings should not be interpreted as independent predictors. Endometrial ultrasonographic features may provide supportive information alongside established clinical factors such as baseline β-hCG.
Background
This paper addresses the clinical question of how pre-treatment endometrial ultrasonographic features relate to the success of methotrexate treatment in tubal ectopic pregnancies. Previous studies have indicated variability in treatment success with methotrexate, but the specific associations with ultrasound features had not been clearly established. Understanding these associations could help refine treatment protocols and improve outcomes for women with ectopic pregnancies.
Methods
This prospective case series included 177 women diagnosed with tubal ectopic pregnancy who were treated with a single intramuscular dose of methotrexate (50 mg/m²). The study took place across two tertiary hospitals in Isfahan, Iran, from January to December 2024. Transvaginal ultrasonography was employed to assess endometrial thickness and classify the endometrial echo pattern, with treatment success defined as a ≥15% decline in serum β-hCG from day 4 to day 7 post-treatment.
Results
The primary endpoint revealed that treatment success occurred in 94 of 177 women (53.1%). Responders exhibited a median baseline β-hCG concentration of 500 mIU/mL compared to 1400 mIU/mL in non-responders (P < 0.001). Additionally, responders had a thinner endometrium (7 mm) compared to non-responders (9 mm; P = 0.009). A higher proportion of responders (65.9%) had a homogeneous endometrial appearance compared to 49.4% of non-responders (P = 0.026).
Interpretation
The findings suggest that lower baseline β-hCG concentrations, thinner endometrial thickness, and a homogeneous endometrial appearance may be associated with successful treatment outcomes following methotrexate administration. However, the effect sizes for these associations must be interpreted cautiously, as the study did not control for confounding variables through multivariable analysis. This limitation raises questions about the independence of these associations and their clinical relevance in practice.
Key findings
- Treatment success occurred in 94 of 177 women (53.1%).
- Responders had lower median baseline β-hCG concentrations (500 versus 1400 mIU/mL; P < 0.001).
- Responders had thinner endometrium (7 versus 9 mm; P = 0.009).
- 65.9% of responders had a homogeneous endometrial appearance compared to 49.4% of non-responders (P = 0.026).
- Baseline β-hCG (P = 0.003), ectopic pregnancy size (P = 0.013), and homogeneous endometrial appearance (P = 0.027) were significantly associated with treatment success.
- Endometrial thickness showed borderline evidence of association (P = 0.0498).
Limitations
- No multivariable model fitted, limiting interpretation of independent predictors.
- Sample limited to two tertiary hospitals, affecting generalizability.
- Prospective case series design may introduce selection bias.